Biosimilars Opportunity In China, But Regulatory Pathway Still Missing - Biosimilars Asia Conference
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Biosimilars makers foresee a huge opportunity in the emerging pharma market of China, which is expected to grow by 22-25% as of 2014, speakers from the IBC Biosimilars Asia Conference in Shanghai said May 24